Under construction – not a live service
Sign in
Taking people in AustriaNo phase

Tests an early hospital discharge plan after a heart attack

Tests discharging adults with heart attack about 24 hours after invasive treatment.

Plain-language title generated from the registry record
Registry title: Fast Discharge After Acute Myocardial Infarction Discharge MI

Key facts

Where
Feldkirch, Graz, Innsbruck, Salzburg, Schwarzach im Pongau, Wels, and Wiener Neustadt, AustriaSee the 7 sites

Where in Austria

  • Academic Teaching Hospital FeldkirchFeldkirch, AustriaTaking people
  • Medical University of GrazGraz, AustriaTaking people
  • Medical University of InnsbruckInnsbruck, AustriaTaking people
  • Paracelsus Medical University SalzburgSalzburg, AustriaTaking people
  • Cardinal Schwarzenberg Hospital SchwarzachSchwarzach im Pongau, AustriaNot yet recruiting
  • University Teaching Hospital Wels-GrieskirchenWels, AustriaTaking people
  • Hospital Wiener NeustadtWiener Neustadt, AustriaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Medical University Innsbruck
Trial code
NCT06744322
Record updated
16 March 2026
Original description
To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.Read full original descriptionShow less

Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

Inclusion: Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC; Age ≥ 18 years at time of consent; Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow; Ability to understand and willingness to sign and date written informed consent.

Exclusion: Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest); PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli); Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI; Ongoing quantitative disorders of consciousness (somnolence, sopor, coma); Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3; Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors); Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema); Pregnancy; Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge; Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team.

ClinicalTrials.gov NCT06744322